Skip to main content
EMA Logo
  • Medicines
    Medicines

    • Search
    • Download
    • What we publish and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    Human regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Herbal products
  • Veterinary regulatory
    Veterinary regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    Committees

    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    News & events

    • News and press releases
    • Events
    • What's new
    • Committee highlights
    • Therapeutic areas: latest updates
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    Partners & networks

    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Academia
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    About us

    • What we do
    • Who we are
    • How we work
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • FAQs
    • Contacts

COVID-19 pandemic

All info here

QUICK LINKS

  • Latest updates
  • Vaccines
  • Treatments
  • Guidance for developers and companies
  • CHMP highlights: May 2022
    CHMP slider image
    MEDICINES |COMMITTEES

    CHMP highlights: May 2022

  • CHMP highlights: May 2022
    CHMP slider image
    MEDICINES |COMMITTEES

    CHMP highlights: May 2022

    EMA's human medicines committee (CHMP) recommended 9 new medicines for approval in the EU, including 3 medicines to treat rare genetic diseases at its May 2022 meeting

  • ICMRA-WHO statement on COVID-19 vaccine confidence
    ICMRA WHO
    ICMRA |Regulatory

    ICMRA-WHO statement on COVID-19 vaccine confidence

  • ICMRA-WHO statement on COVID-19 vaccine confidence
    ICMRA WHO
    ICMRA |Regulatory

    ICMRA-WHO statement on COVID-19 vaccine confidence

    The International Coalition of Medicines Regulatory Authorities (ICMRA) and WHO issued a statement to support healthcare professionals to enhance public confidence in COVID-19 vaccines

  • EMA’s Veterinary Committee elects new chair
    CVMP chairman
    Committee |Regulatory

    EMA’s Veterinary Committee elects new chair

  • EMA’s Veterinary Committee elects new chair
    CVMP chairman
    Committee |Regulatory

    EMA’s Veterinary Committee elects new chair

    EMA’s Committee for Veterinary Medicinal Products (CVMP) elected Gerrit Johan Schefferlie from the Dutch Medicines Evaluation Board as its chair for a three-year mandate

  • Monthly safety update for COVID-19 vaccines
    safety updates COVID-19
    COVID-19 |Vaccines

    Monthly safety update for COVID-19 vaccines

  • Monthly safety update for COVID-19 vaccines
    safety updates COVID-19
    COVID-19 |Vaccines

    Monthly safety update for COVID-19 vaccines

    EMA has released its latest safety update report on all COVID-19 vaccines authorised in the EU. It provides an overview of the safety monitoring of these vaccines

Search for medicines
Search for information on human, veterinary or herbal medicines.
What's new
Find all the latest news and updates published on this website in one place.
FAQs
Find answers to the most frequently asked questions we receive.

Latest news

  • List item
    20/05/2022 COVID-19

    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022

    Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its May 2022 meeting. A recommendation for marketing authorisation was adopted for Cevenfacta (eptacog beta (activated))...

  • List item
    20/05/2022

    First therapy to treat two types of Niemann-Pick disease, a rare genetic metabolic disorder

    EMA has recommended granting a marketing authorisation in the European Union (EU) for Xenpozyme (olipudase alfa), a therapy for the treatment of non-central nervous system (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD), a rare and...

  • List item
    20/05/2022

    Synchron Research Service: suspension of medicines over flawed studies

    EMA’s human medicines committee (CHMP) has recommended the suspension of the marketing authorisations of several generic medicines tested by Synchron Research Services, a contract research organisation (CRO) located in Ahmedabad, India. The...

  • List item
    20/05/2022

    First therapy to treat rare genetic nervous system disorder AADC deficiency

    EMA has recommended granting a marketing authorisation in the European Union (EU) for Upstaza (eladocagene exuparvovec), a therapy for the treatment of adult and paediatric patients with severe aromatic L-amino acid decarboxylase (AADC) deficiency...

  • List item
    20/05/2022

    First treatment for children with Progeria or progeroid like syndromes (rare premature aging syndromes)

    EMA has recommended granting a marketing authorisation in the European Union (EU) under exceptional circumstances for Zokinvy (lonafarnib), a treatment for patients with a genetically confirmed diagnosis of Hutchinson-Gilford Progeria Syndrome or...

  • List item
    17/05/2022 COVID-19

    International regulators and WHO: support healthcare professionals to enhance public confidence in COVID-19 vaccines

    EMA has endorsed a statement for healthcare professionals jointly developed by the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO) . The statement is aimed to help healthcare professionals...

  • Load more news

Information for you

Patients and carers
Featured news and updates for patients and carers
Healthcare professionals
Featured news and updates for healthcare professionals, including doctors, nurses and pharmacists
Animal health professionals
Featured news and updates for animal health professionals and users of veterinary medicines such as pet owners
Pharmaceutical industry
Featured news and updates for pharmaceutical industry stakeholders active in the human and veterinary medicines fields
Media
Featured news and updates for journalists with a professional interest in the development and availability of medicines in the European Union
Academia
Featured news and updates for European academics and researchers in the field of medicine development

Key content

  • List item

    Product emergency hotline

  • List item

    UK’s withdrawal from the EU

  • List item

    PRIME: Priority medicines

  • List item

    Pharmacovigilance (safety monitoring)

  • List item

    Data on medicines

  • List item

    Clinical data publication

  • List item

    Careers

Services & databases

  • List item

    Clinical Trials website

  • List item

    Account Management portal

  • List item

    eSubmission

  • List item

    EudraVigilance (human)

  • List item

    EudraVigilance Veterinary

  • List item

    Veterinary Medicines information website

  • List item

    Suspected adverse drug reactions database

  • List item

    Clinical data

  • List item

    SPOR data management services

  • List item

    Service Desk

  • List item

    IRIS platform

  • List item

    Public register of parallel distribution notices

  • List item

    European Vaccination Information Portal

How does EMA work?

  • List item

    What we do

  • List item

    Our role in authorisation of medicines

  • List item

    Who we are

  • List item

    Our scientific experts

  • List item

    How we work

  • List item

    What we publish

Product emergency hotline
outside working hours
  • About us
  • What we do
  • Careers
  • Committees
  • Regulatory network
  • Frequently asked questions
  • Search tips
  • Glossaries
  • About this website
  • Privacy
  • Access to documents
  • Contacts
  • Send a question
  • EMA Service Desk (system support)

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us

Postal address and deliveries

Business hours and holidays

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.
RSS feed Twitter YouTube LinkedIn
© 1995-2022 European Medicines Agency
European Union agencies network
European Union agencies network
An agency of the European Union
European Union flag